BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25597981)

  • 1. Defibrillator patients should not be denied a peaceful death.
    Westerdahl AK; Sutton R; Frykman V
    Int J Cardiol; 2015 Mar; 182():440-6. PubMed ID: 25597981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deactivation of Implantable Cardioverter Defibrillator in Patients With Terminal Diagnoses.
    Trussler A; Alexander B; Campbell D; Alhammad N; Enriquez A; Chacko S; Garrett T; Simpson C; Redfearn D; Abdollah H; Herx L; Baranchuk A
    Am J Cardiol; 2019 Oct; 124(7):1064-1068. PubMed ID: 31353003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deactivation of implantable defibrillators at end of life - Can we do better?
    Kinch Westerdahl A; Magnsjö J; Frykman V
    Int J Cardiol; 2019 Sep; 291():57-62. PubMed ID: 30853295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ethics of unilateral implantable cardioverter defibrillators and cardiac resynchronization therapy with defibrillator deactivation: patient perspectives.
    Daeschler M; Verdino RJ; Kirkpatrick JN
    Europace; 2017 Aug; 19(8):1343-1348. PubMed ID: 27915265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving implantable cardioverter defibrillator deactivation discussions in admitted patients made DNR and comfort care.
    Choi DY; Wagner MP; Yum B; Jannat-Khah DP; Mazique DC; Crossman DJ; Lee JI
    BMJ Open Qual; 2019; 8(4):e000730. PubMed ID: 31922034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in time in the management of the implantable cardioverter defibrillator in the last phase of life: a retrospective study of medical records.
    Stoevelaar R; Brinkman-Stoppelenburg A; van Driel AG; Theuns DA; Bhagwandien RE; van Bruchem-Visser RL; Lokker IE; van der Heide A; Rietjens JA
    Eur J Cardiovasc Nurs; 2019 Aug; 18(6):449-457. PubMed ID: 30995145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-of-life care in patients with implantable cardioverter defibrillators: a MADIT-II substudy.
    Sherazi S; McNitt S; Aktas MK; Polonsky B; Shah AH; Moss AJ; Daubert JP; Zareba W
    Pacing Clin Electrophysiol; 2013 Oct; 36(10):1273-9. PubMed ID: 23731284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deactivation of implantable cardioverter-defibrillators at end of life.
    Pettit SJ; Jackson CE; Gardner RS
    Future Cardiol; 2013 Nov; 9(6):885-96. PubMed ID: 24180544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deactivation of implantable cardioverter defibrillators in terminal illness and end of life care.
    Kirkpatrick JN; Gottlieb M; Sehgal P; Patel R; Verdino RJ
    Am J Cardiol; 2012 Jan; 109(1):91-4. PubMed ID: 21943937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implantable cardioverter-defibrillator deactivation at the end of life: ethical, clinical and communication issues].
    Romanò M; Piga MA; Bertona R; Negro R; Ruggeri C; Zorzoli F; Villani R
    G Ital Cardiol (Rome); 2017 Feb; 18(2):139-149. PubMed ID: 28398367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-of-life decisions in ICD patients with malignant tumors.
    Kobza R; Erne P
    Pacing Clin Electrophysiol; 2007 Jul; 30(7):845-9. PubMed ID: 17584265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICD deactivation: review of literature and clinical recommendations.
    Thanavaro JL
    Clin Nurs Res; 2013 Feb; 22(1):36-50. PubMed ID: 22645402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Original research: deactivation of ICDs at the end of life: a systematic review of clinical practices and provider and patient attitudes.
    Russo JE
    Am J Nurs; 2011 Oct; 111(10):26-35. PubMed ID: 21926561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deactivating the implantable cardioverter-defibrillator: a biofixture analysis.
    Paola FA; Walker RM
    South Med J; 2000 Jan; 93(1):20-3. PubMed ID: 10653059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life.
    Kinch Westerdahl A; Sjöblom J; Mattiasson AC; Rosenqvist M; Frykman V
    Circulation; 2014 Jan; 129(4):422-9. PubMed ID: 24243857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The attitudes of neonatal professionals towards end-of-life decision-making for dying infants in Taiwan.
    Huang LC; Chen CH; Liu HL; Lee HY; Peng NH; Wang TM; Chang YC
    J Med Ethics; 2013 Jun; 39(6):382-6. PubMed ID: 22562946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinician Attitudes Regarding ICD Deactivation in DNR/DNI Patients.
    Bradley A; Marks A
    J Hosp Med; 2017 Jul; 12(7):498-502. PubMed ID: 28699936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' experiences of the implantable cardioverter defibrillator (ICD); with a focus on battery replacement and end-of-life issues.
    Fluur C; Bolse K; Strömberg A; Thylén I
    Heart Lung; 2013; 42(3):202-7. PubMed ID: 23273655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey.
    Kelley AS; Reid MC; Miller DH; Fins JJ; Lachs MS
    Am Heart J; 2009 Apr; 157(4):702-8.e1. PubMed ID: 19332199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.